Yoshinori Fujiwara

Yoshinori Fujiwara

Auto-generated profile, based on publicly available information

Yoshinori Fujiwara

Department of Digestive Surgery, Kawasaki Medical School, Kurashiki, Okayama 701‑0192, Japan

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in World Journal of Gastrointestinal Oncology
Verified
Journal Article
Open access
YFYoshinori Fujiwara
Yoshinori Fujiwara
SFShuichi Fukuda
Shuichi Fukuda
MTMasanori Tsujie
Masanori Tsujie
HIHajime Ishikawa
Hajime Ishikawa
KKKotaro Kitani
Kotaro Kitani
MIMasatoshi Inoue
Masatoshi Inoue
Effects of age on survival and morbidity in gastric cancer patients undergoing gastrectomy

1 November 1995 in Transplantation
Verified
Journal Article
Closed access
MKMasato Kusunoki
Masato Kusunoki
HIHiromitsu Ishii
Hiromitsu Ishii
KNKoji Nakao
Koji Nakao
YFYoshinori Fujiwara
Yoshinori Fujiwara
TYTakehira Yamamura
Takehira Yamamura
JUJoji Utsunomiya
Joji Utsunomiya
We previously found that the contractile motility of the jejunum was increased 4 weeks after transplantation, and that the dominant intrinsic neural component was changed from cholinergic to nonadrenergic, noncholinergic (NANC). The present study investigated the long-term effects of transplantation on jejunal motility using rats that survived for 2 years after surgery. Jejunal strips were harvested from various groups of rats, and intestinal motility was assessed by electrical transmural stimulation. Stimulation produced a similar increase of contraction at 4 weeks and 2 years after grafting. Pretreatment with atropine showed that the cholinergic component of contraction was 45%, 24%, 32%, and 24% in controls, rats 4 weeks after transplantation, 2-year-old controls, and rats 2 years after transplantation, respectively. The NANC component (obtained with atropine and guanethidine) in each group was, respectively, 56%, 73%, 60%, and 69%. The actual value of the tetrodotoxin-insensitive myogenic component was significantly increased at 2 years after transplantation. A substance P antagonist ([Arg6, D-Trp7,9, Mephe8], substance P 6-11), inhibited most of the NANC contraction after transplantation. These results suggested that substance P has a key role in the motility of transplanted small bowel throughout the life of the grafts.

21 May 2013 in Molecular and Clinical Oncology
Verified
Journal Article
Open access
PDF file
YFYoshinori Fujiwara
Yoshinori Fujiwara
RYReigetsu Yoshikawa
Reigetsu Yoshikawa
NKNorihiko Kamikonya
Norihiko Kamikonya
TNTsuyoshi Nakayama
Tsuyoshi Nakayama
KKKotaro Kitani
Kotaro Kitani
MIMasatoshi Inoue
Masatoshi Inoue
In order to improve the survival of esophageal cancer patients, a trimodality therapy consisting of esophagectomy in combination with neoadjuvant chemoradiotherapy (CRT) has been developed. In this study, we evaluated whether neoadjuvant CRT improved the outcomes of patients with resectable esophageal squamous cell carcinoma (ESCC) compared to surgery alone. Eighty‑eight patients with resectable ESCC were treated with either neoadjuvant CRT followed by surgical resection (Group A, n=52), or surgery alone (Group B, n=36). CRT consisted of 5‑fluorouracil (5‑FU, 500 mg/m2 on days 1‑5) and cisplatin (CDDP, 10‑20 mg/kg body weight on days 1‑5), repeated after 3 weeks. Survival analysis was performed using the log‑rank test with the Kaplan‑Meier method. The clinical response of the primary tumor and metastatic nodes was 80.8%. The postoperative complications profile was similar between the two groups, except for anastomotic leakage. The median survival time (MST) was not reached in Group A and was 27.4 months in Group B. The estimated 5‑year overall survival (OS) rate was 50.3% in Group A and 39.9% in Group B (P=0.134). As regards stage II̸III disease, Group A exhibited a better disease‑free survival (DFS) compared to Group B (5‑year DFS: 57.2% in Group A vs. 31.4% in Group B; P=0.025). Simultaneous locoregional and distant recurrences were more common in the surgery alone group (Group B, P=0.047). Neoadjuvant CRT with 5‑FU and CDDP did not contribute to a better prognosis in patients with resectable ESCC. However, it may be beneficial for patients with stage II̸III disease.

3 November 2022 in Esophagus
Verified
Journal Article
Closed access
PDF file
YFYoshinori Fujiwara
Yoshinori Fujiwara
SEShunji Endo
Shunji Endo
MHMasaharu Higashida
Masaharu Higashida
HKHisako Kubota
Hisako Kubota
KYKazuhiko Yoshimatsu
Kazuhiko Yoshimatsu
TUTomio Ueno
Tomio Ueno

17 March 2021 in Gastrointestinal Tumors
Verified
Journal Article
Open access
PDF file
YFYoshinori Fujiwara
Yoshinori Fujiwara
MHMasaharu Higashida
Masaharu Higashida
HKHisako Kubota
Hisako Kubota
YOYuko Okamoto
Yuko Okamoto
SMShumei Mineta
Shumei Mineta
TUTomio Ueno
Tomio Ueno
Introduction: We studied whether perioperative nutritional, immunological factors or postoperative inflammatory responses predicted esophageal cancer (EC) progression and prognosis in patients who received esophagectomies. Methods: We evaluated preoperative prognostic nutritional index (PNI), BMI, neutrophil-to-lymphocyte ratio (NLR), intraoperative blood loss, postoperative C-reactive protein (CRP) max, recurrence-free survival (RFS), and overall survival (OS) in 111 patients with pStage I–IV squamous cell EC who received esophagectomies. Optimal cutoff values for each continuous parameter were determined by receiver operating characteristic curves and Youden indices. Univariate and multivariate Cox analyses were used to derive independent prognostic factors. Propensity score matching using inverse probability of treatment weighting was used in groups divided by Youden indices, as appropriate. Results: Cutoff values of continuous variables were NLR: 2.27, PNI: 44.2, blood loss: 159 mL, and CRPmax: 21.7 mg/dL. In multivariate analyses, PNI, CRPmax, and intraoperative blood loss were independent prognostic factors for OS and RFS. Among patients with stage II–IV disease, low PNI was associated with shorter RFS. Postoperative respiratory complications were associated with both higher CRP and shorter RFS. Discussion/Conclusions: Low preoperative PNI and high postoperative inflammatory response were associated with postoperative EC progression after esophagectomy. Preoperative nutritional interventions or suppression of postoperative inflammatory response, including respiratory complications, may improve patient prognosis.

1 June 2012 in Oncology Reports
Verified
Journal Article
Open access
PDF file
YFYoshinori Fujiwara
Yoshinori Fujiwara
RYReigetsu Yoshikawa
Reigetsu Yoshikawa
NKNorihiko Kamikonya
Norihiko Kamikonya
TNTsuyoshi Nakayama
Tsuyoshi Nakayama
KKKotaro Kitani
Kotaro Kitani
TYTakehira Yamamura
Takehira Yamamura
The prognosis of advanced esophageal cancer patients is poor. Trimodality therapy of surgical resection plus neoadjuvant chemoradiotherapy (CRT) has been developed to improve survival through locoregional control, leading to prevention of micrometastasis. We investigated whether or not neoadjuvant CRT led to survival benefits in TNM stage II/III esophageal cancer patients. We retrospectively reviewed 62 patients with stage II or III esophageal squamous cell carcinoma (ESCC) treated with neoadjuvant CRT. All patients received esophagectomy 4-7 weeks after CRT consisting of 40 Gy irradiation and chemotherapy (5-FU, 500 mg/m2/day, days 1-5 and cisplatin, 10-20 mg/body, days 1-5). Clinical response and survival rates were analyzed using Kaplan-Meier methods, with p<0.05 considered as significant. The clinical effect rate of CRT for both primary tumors and metastatic nodes was 82.3%. Operative and hospital mortality rates were 1.65 and 6.5%, respectively. The 3-year overall survival (OS) and disease-free survival (DFS) rates were 52.6 and 49.2%, respectively. A significant difference was noted between stages II and III for both OS and DFS. The 5-year OS rates were 64.2% for stage II, 33.1% for stage III (T4 and non-T4) and 46.9% for stage III (non-T4 only) patients. The depth of tumor invasion (T3 vs. T4), resectability (R0 vs. R1, R2), lymph node metastasis (positive vs. negative), and the effect of CRT were proven to be independent prognostic factors for univariate analysis, with resectability and the effect of CRT for multivariate analysis. These data suggest that CRT in stage II/III (non-T4) ESCC patient contributed to tumor shrinkage, leading to higher resectability and longer survival. Neoadjuvant CRT appears to be a promising option for these patients.